Literature DB >> 33693921

Schizophrenia and the Environment: Within-Person Analyses May be Required to Yield Evidence of Unconfounded and Causal Association-The Example of Cannabis and Psychosis.

Jim van Os1,2,3, Lotta-Katrin Pries2, Margreet Ten Have4, Ron de Graaf4, Saskia van Dorsselaer4, Maarten Bak2,5, Hans-Ulrich Wittchen6, Bart P F Rutten2, Sinan Guloksuz2,7.   

Abstract

Hypotheses about the link between cannabis use and psychosis apply to the within-person level but have been tested mostly at the between-person level. We used a within-person design, in which a person serves as his own control, thus removing the need to consider confounding by any fixed (genetic and nongenetic) characteristic to study the prospective association between cannabis use and the incidence of attenuated psychotic experiences, and vice versa, adjusted for time-varying confounders. We combined 2 general population cohorts (at baseline: Early Developmental Stages of Psychopathology Study, n = 1395; Netherlands Mental Health Survey and Incidence Study-2, n = 6603), which applied a similar methodology to study cannabis use and attenuated psychotic experiences with repeated interviews (T0, T1, T2, and T3) over a period of approximately 10 years. The Hausman test was significant for the adjusted models, indicating the validity of the fixed-effects model. In the adjusted fixed-effects model, prior cannabis use was associated with psychotic experiences (aOR = 7.03, 95% CI: 2.39, 20.69), whereas prior psychotic experiences were not associated with cannabis use (aOR = 0.59, 95% CI: 0.21, 1.71). Longitudinal studies applying random-effects models to study associations between risk factors and mental health outcomes, as well as reverse causality, may not yield precise estimates. Cannabis likely impacts causally on psychosis but not the other way round.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Entities:  

Keywords:  cannabis; drug use; epidemiology; psychosis; within-person effects

Year:  2021        PMID: 33693921     DOI: 10.1093/schbul/sbab019

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  6 in total

1.  Changes in Expression of DNA-Methyltransferase and Cannabinoid Receptor mRNAs in Blood Lymphocytes After Acute Cannabis Smoking.

Authors:  Robert C Smith; Henry Sershen; David S Janowsky; Abel Lajtha; Matthew Grieco; Jon A Gangoiti; Ilya Gertsman; Wynnona S Johnson; Thomas D Marcotte; John M Davis
Journal:  Front Psychiatry       Date:  2022-07-04       Impact factor: 5.435

2.  Digital phenotyping correlations in larger mental health samples: analysis and replication.

Authors:  Danielle Currey; John Torous
Journal:  BJPsych Open       Date:  2022-06-03

3.  Childhood maltreatment mediates the effect of the genetic background on psychosis risk in young adults.

Authors:  Mattia Marchi; Laurent Elkrief; Anne Alkema; Willemijn van Gastel; Chris D Schubart; Kristel R van Eijk; Jurjen J Luykx; Susan Branje; Stefanos Mastrotheodoros; Gian M Galeazzi; Jim van Os; Charlotte A Cecil; Patricia J Conrod; Marco P Boks
Journal:  Transl Psychiatry       Date:  2022-06-01       Impact factor: 7.989

4.  Editorial: Gone to Pot: Examining the Association Between Cannabis Use and Medical/Psychiatric Disorders.

Authors:  Rajiv Radhakrishnan; Sinan Guloksuz; Deepak C D'Souza; Jim van Os
Journal:  Front Psychiatry       Date:  2022-02-08       Impact factor: 4.157

5.  Development of a Mobile Assessment Tool for Understanding Social Comparison Processes Among Individuals With Schizophrenia: Two-Phase Survey Study.

Authors:  Danielle Arigo; John Torous
Journal:  JMIR Form Res       Date:  2022-05-02

6.  Using Experience Sampling Methodology Data to Characterize the Substance Use of Youth With or At-Risk of Psychosis.

Authors:  David M Weiss; Elizabeth Bernier; Douglas R Robbins; Katherine M Elacqua; Kelsey A Johnson; Kate Powers; Raquelle I Mesholam-Gately; Kristen A Woodberry
Journal:  Front Psychiatry       Date:  2022-05-03       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.